Sareum Holdings PLC (LSE:SAR) has announced the discontinuation of its 16-week GLP preclinical toxicology study for SDC-1801 after safety issues were identified in control-group animals that received only an inactive dosing solution. The company has launched an investigation to determine the root cause of these findings and intends to restart the study with a new research provider. Sareum expects to complete the revised program using its existing cash resources.
While the development marks a setback, Sareum highlighted that no safety concerns were observed in earlier Phase 1 trials. The company remains committed to advancing SDC-1801 into Phase 2 clinical development for psoriasis once the toxicology study is successfully completed.
Despite promising scientific progress, Sareum continues to face significant financial headwinds, including the absence of revenue and ongoing losses. Although technical indicators suggest some short-term strength and recent strategic updates offer optimism, valuation challenges remain due to negative earnings.
About Sareum Holdings PLC
Sareum Holdings is a clinical-stage biotechnology company headquartered in Cambridge, UK. It focuses on the development of next-generation kinase inhibitors targeting autoimmune diseases and cancer, with a goal of advancing innovative therapies into clinical stages and eventual commercialization.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply